2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100813
    Saclofen 125464-42-8 99.70%
    Saclofen is an orally active and a competitive GABAB receptor antagonist with an IC50 of 7.8 μM. Saclofen has weak antagonistic effects on GABAB1b and GABAB2 heterodimeric recombinant receptors. Saclofen inhibits the binding of Baclofen (HY-B0007) to rat cerebellar membranes and blocks Baclofen-induced circadian phase shifts, and exhibits anti-inflammatory and analgesic effects in rats.
    Saclofen
  • HY-110247
    TRAF-STOP inhibitor 6877002 433249-94-6 99.67%
    TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway.
    TRAF-STOP inhibitor 6877002
  • HY-110313
    SB-747651A dihydrochloride 1781882-72-1 ≥99.0%
    SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research.
    SB-747651A dihydrochloride
  • HY-113212
    Ursocholic acid 2955-27-3 ≥98.0%
    Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis.
    Ursocholic acid
  • HY-113491
    3-Phosphoglyceric acid 820-11-1 99.88%
    3-Phosphoglyceric acid is a metabolic intermediate in both glycolysis and the Calvin cycle. 3-Phosphoglyceric acid is involved in alveolar macrophage epigenetic regulation.
    3-Phosphoglyceric acid
  • HY-117626
    LP-935509 1454555-29-3 99.74%
    LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research.
    LP-935509
  • HY-123617
    AZ8838 2100285-41-2 99.30%
    AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2.
    AZ8838
  • HY-129960
    L-Selenocystine 29621-88-3
    L-Selenocystine is a selenium-containing amino acid. L-Selenocystine has redox properties. L-Selenocystine is cytotoxic to various tumor cells and can induce the production of ROS and apoptosis. L-Selenocystine can block the Nrf2 and autophagy pathways. L-Selenocystine has anti-tumor activity.
    L-Selenocystine
  • HY-148045
    TLR9-IN-1 2226366-86-3 99.80%
    TLR9-IN-1 is a potent and selective TLR9 inhibitor with an IC50 value of 7 nM for human TLR9. TLR9-IN-1 can be used for researching diseases associated with undesirable immune response.
    TLR9-IN-1
  • HY-148141
    JPE-1375 1254036-23-1 99.94%
    JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases.
    JPE-1375
  • HY-B0157A
    Ketotifen fumarate 34580-14-8 99.92%
    Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.
    Ketotifen fumarate
  • HY-P99111
    Golimumab 476181-74-5 99.71%
    Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.
    Golimumab
  • HY-117295A
    7-Fluorotryptamine hydrochloride 159730-09-3 98.86%
    7-Fluorotryptamine hydrochloride is a potent agonist of GPRC5A. 7-Fluorotryptamine hydrochloride induces GPRC5A-mediated β-arrestin recruitment. 7-Fluorotryptamine hydrochloride can be used for research of immune and cancer signaling.
    7-Fluorotryptamine hydrochloride
  • HY-W015239
    KAT8-IN-1 605-62-9 99.40%
    KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC50s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases.
    KAT8-IN-1
  • HY-W145667
    Mannan 9036-88-8 98.10%
    Mannan is an orally active polysaccharide compound that binds to the mannose receptor (MR). Mannan promotes bacterial uptake and endosomal degradation by binding to MR, thereby enhancing the production of IL-12 in immune cells. Mannan enhances ROS production. Mannan modulates immunity, inhibits Aflatoxin B1 (HY-N6615)-induced toxicity, and reduces lipid.
    Mannan
  • HY-W010347S
    DL-Homocysteine-d4 416845-90-4 ≥98.0%
    DL-Homocysteine-d4 is the deuterium labeled DL-Homocysteine. DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain[1][2].
    DL-Homocysteine-d4
  • HY-10017
    SCH 546738 906805-42-3 98.71%
    SCH 546738 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.
    SCH 546738
  • HY-10403
    PH-797804 586379-66-0 98.92%
    PH-797804 is a ATP-competitive, selective p38α/p38β inhibitor (IC50=26 nM and Ki=5.8 nM for p38α; Ki=40 nM for p38β) and does not inhibit JNK2.
    PH-797804
  • HY-10582
    Flurbiprofen 5104-49-4 99.98%
    Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer.
    Flurbiprofen
  • HY-106420
    16,16-Dimethyl prostaglandin E2 39746-25-3 ≥99.0%
    16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2) is an orally active vertebrate Hematopoietic stem cells (HSCs) homeostasis critical regulator. 16,16-Dimethyl prostaglandin E2 can act through EP2/EP4 and has an interaction with the Wnt pathway.
    16,16-Dimethyl prostaglandin E2
Cat. No. Product Name / Synonyms Application Reactivity